Roche’s VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic NSCLC eligible for Libtayo

CAP publishes guideline for PD-L1 testing for lung cancer

The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, Pulmonary Pathology Society, Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations for the testing of immunotherapy biomarkers, including programmed cell death ligand-1 and tumor mutation burden in patients with non-small cell lung carcinoma.

April 19, 2024

Vol.50 No.16

Clinical Roundup

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Non-classical mutations are present in 20-30% of all patients with epidermal growth factor receptor-mutated non-small cell lung cancer, according to an analysis of real-world evidence presented by Black Diamond Therapeutics, Inc. at the American Association of Cancer Research annual meeting.

April 12, 2024

Vol.50 No.15

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.

March 29, 2024

Vol.50 No.13

Drugs & Targets

FDA approves Rybrevant for first-line treatment of EGFR-m NSCLC

FDA approved Rybrevant (amivantamab-vmjw) with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor, or EGFR, exon 20 insertion mutations, as detected by an FDA-approved test.

March 08, 2024

Vol.50 No.10

Drugs & Targets

Elipses’s selective RET inhibitor EP0031/A400 granted Fast Track designation in NSCLC

FDA granted the next-generation selective RET inhibitor EP0031/A400 Fast Track designation for the potential treatment of RET-fusion positive non-small cell lung cancer.

March 08, 2024

Vol.50 No.10

Drugs & Targets

FDA approves Tagrisso + chemo for EGFR-mutated NSCLC

FDA approved Tagrisso (osimertinib) with platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

February 23, 2024

Vol.50 No.08

Roche’s VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic NSCLC eligible for Libtayo

YOU MAY BE INTERESTED IN

CAP publishes guideline for PD-L1 testing for lung cancer

Non-classical mutations present in 20-30% of all patients with EGFR-mutated NSCLC, analysis shows

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

FDA approves Rybrevant for first-line treatment of EGFR-m NSCLC

Elipses’s selective RET inhibitor EP0031/A400 granted Fast Track designation in NSCLC

FDA approves Tagrisso + chemo for EGFR-mutated NSCLC

Renew today!

Subscriber content

Login